Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW)
TWD 28.8
(-1.54%)
TWD 28.8
(-1.54%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 5.17 Billion TWD | 13.31% |
| 2022 | 4.56 Billion TWD | 4.19% |
| 2021 | 4.38 Billion TWD | 39.2% |
| 2020 | 3.14 Billion TWD | -8.48% |
| 2019 | 3.43 Billion TWD | 6.75% |
| 2018 | 3.22 Billion TWD | -6.57% |
| 2017 | 3.44 Billion TWD | 26.5% |
| 2016 | 2.72 Billion TWD | -5.05% |
| 2015 | 2.87 Billion TWD | -10.5% |
| 2014 | 3.2 Billion TWD | 5.5% |
| 2013 | 3.04 Billion TWD | 0.82% |
| 2012 | 3.01 Billion TWD | 26.96% |
| 2011 | 2.37 Billion TWD | 0.19% |
| 2010 | 2.37 Billion TWD | 2.52% |
| 2009 | 2.31 Billion TWD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 5.22 Billion TWD | 1.05% |
| 2024 Q2 | 4.99 Billion TWD | -4.42% |
| 2023 Q4 | 5.17 Billion TWD | 2.69% |
| 2023 FY | 5.17 Billion TWD | 13.31% |
| 2023 Q1 | 5.01 Billion TWD | 9.84% |
| 2023 Q3 | 5.03 Billion TWD | 2.21% |
| 2023 Q2 | 4.92 Billion TWD | -1.72% |
| 2022 Q2 | 4.4 Billion TWD | -3.86% |
| 2022 Q1 | 4.57 Billion TWD | 4.51% |
| 2022 FY | 4.56 Billion TWD | 4.19% |
| 2022 Q4 | 4.56 Billion TWD | 3.06% |
| 2022 Q3 | 4.42 Billion TWD | 0.61% |
| 2021 Q1 | 3.32 Billion TWD | 5.51% |
| 2021 FY | 4.38 Billion TWD | 39.2% |
| 2021 Q3 | 4.23 Billion TWD | 11.97% |
| 2021 Q4 | 4.38 Billion TWD | 3.42% |
| 2021 Q2 | 3.78 Billion TWD | 13.94% |
| 2020 Q3 | 2.98 Billion TWD | -2.85% |
| 2020 FY | 3.14 Billion TWD | -8.48% |
| 2020 Q1 | 3.44 Billion TWD | 0.29% |
| 2020 Q2 | 3.07 Billion TWD | -10.87% |
| 2020 Q4 | 3.14 Billion TWD | 5.38% |
| 2019 Q3 | 3.33 Billion TWD | -0.49% |
| 2019 Q4 | 3.43 Billion TWD | 3.01% |
| 2019 FY | 3.43 Billion TWD | 6.75% |
| 2019 Q1 | 3.3 Billion TWD | 2.68% |
| 2019 Q2 | 3.35 Billion TWD | 1.42% |
| 2018 Q1 | 3.31 Billion TWD | -3.8% |
| 2018 Q4 | 3.22 Billion TWD | 1.97% |
| 2018 Q3 | 3.15 Billion TWD | -5.59% |
| 2018 FY | 3.22 Billion TWD | -6.57% |
| 2018 Q2 | 3.34 Billion TWD | 0.89% |
| 2017 Q2 | 2.66 Billion TWD | 0.21% |
| 2017 Q4 | 3.44 Billion TWD | -1.54% |
| 2017 FY | 3.44 Billion TWD | 26.5% |
| 2017 Q3 | 3.5 Billion TWD | 31.29% |
| 2017 Q1 | 2.66 Billion TWD | -2.34% |
| 2016 Q4 | 2.72 Billion TWD | -0.6% |
| 2016 FY | 2.72 Billion TWD | -5.05% |
| 2016 Q3 | 2.74 Billion TWD | 0.26% |
| 2016 Q2 | 2.73 Billion TWD | -4.55% |
| 2016 Q1 | 2.86 Billion TWD | -0.18% |
| 2015 FY | 2.87 Billion TWD | -10.5% |
| 2015 Q2 | 2.71 Billion TWD | -2.03% |
| 2015 Q1 | 2.77 Billion TWD | -13.46% |
| 2015 Q4 | 2.87 Billion TWD | 4.99% |
| 2015 Q3 | 2.73 Billion TWD | 0.55% |
| 2014 Q3 | 3.16 Billion TWD | 2.17% |
| 2014 FY | 3.2 Billion TWD | 5.5% |
| 2014 Q4 | 3.2 Billion TWD | 1.44% |
| 2014 Q2 | 3.09 Billion TWD | -0.2% |
| 2014 Q1 | 3.1 Billion TWD | 2.0% |
| 2013 Q3 | 3.03 Billion TWD | 0.3% |
| 2013 Q4 | 3.04 Billion TWD | 0.01% |
| 2013 FY | 3.04 Billion TWD | 0.82% |
| 2013 Q1 | 3.04 Billion TWD | 0.9% |
| 2013 Q2 | 3.03 Billion TWD | -0.38% |
| 2012 FY | 3.01 Billion TWD | 26.96% |
| 2012 Q2 | 3.18 Billion TWD | 30.86% |
| 2012 Q3 | 3.1 Billion TWD | -2.38% |
| 2012 Q4 | 3.01 Billion TWD | -2.95% |
| 2012 Q1 | 2.43 Billion TWD | 2.4% |
| 2011 Q4 | 2.37 Billion TWD | 4.86% |
| 2011 Q2 | 2.27 Billion TWD | 3.61% |
| 2011 Q1 | 2.19 Billion TWD | -7.33% |
| 2011 FY | 2.37 Billion TWD | 0.19% |
| 2011 Q3 | 2.26 Billion TWD | -0.48% |
| 2010 FY | 2.37 Billion TWD | 2.52% |
| 2010 Q4 | 2.37 Billion TWD | 0.0% |
| 2009 FY | 2.31 Billion TWD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Apex Biotechnology Corp. | 2.29 Billion TWD | -125.148% |
| Sinphar Pharmaceutical Co.,Ltd. | 6.25 Billion TWD | 17.268% |
| Panion & Bf Biotech Inc. | 3.23 Billion TWD | -59.857% |
| GenMont Biotech Incorporation | 1.65 Billion TWD | -212.83% |
| Abnova (Taiwan) Corporation | 1.35 Billion TWD | -281.462% |
| Adimmune Corporation | 9.48 Billion TWD | 45.472% |
| Tanvex BioPharma, Inc. | 2.76 Billion TWD | -87.148% |
| Polaris Group | 9.09 Billion TWD | 43.156% |
| Energenesis Biomedical CO.,LTD. | 828.57 Million TWD | -524.166% |
| UnicoCell Biomed Co., Ltd. | 685.92 Million TWD | -653.963% |
| PELL Bio-Med Technology Co. Ltd. | 1.41 Billion TWD | -264.674% |